Therapeutic Workshop
Changing Paradigms in Lung Cancer Care and Advances in the Pipeline
Friday, October 31, 2008
9:45am - 11:00am
Sea Cliff
Lung cancer still holds the distinction of being one of the nation’s top killers. With multiple targets, single and combination therapies, and maintenance therapy following platinum-based chemotherapy, the treatment paradigm is rapidly changing. Pursuing multiple targets for treatment may be cost-saving but toxicity adds another cost. Where does each therapy fit in and what's the most promising in each type of setting? This panel will focus on the latest data expected to have an impact on lung cancer treatment practices, as well as explore potential future therapeutic options.
Moderator
- Gregory K. Frykman, MD, Senior Vice President, Pharmaceutical and Biotechnology Analyst, Stanford Group Company
Panelists
Industry:
- Philippe Bishop, MD, Vice President, Clinical Development, Avastin, Genentech
- David Apelian, MD, PhD, MBA, Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer, GlobeImmune
Clinician:
- Thomas J. Lynch, MD, Chief Hematology and Oncology, Director of the Center for Thoracic Cancers, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School
- Renato G. Martins, MD, MPH, Medical Director of Thoracic Oncology, Seattle Cancer Care Alliance
Who's Who
Gregory K. Frykman, MD Dr. Frykman covers the pharmaceutical and biotechnology industry with a focus on scientific, medical and regulatory aspects of cancer therapies Formerly, Dr. Frykman worked as a medical reviewer in both the Division of Oncology Drug Products and the Center for Biologics at the Food and Drug Administration. He remains on the active medical staff at Montgomery General Hospital. He earned a bachelor’s degree in Physics and a Medical Doctorate, both from Loma Linda University; an Internal Medicine residency at the USC-Los Angeles County Medical Center; a Medical Oncology fellowship at the Johns Hopkins University; and additional training in Developmental Therapeutics at the National Cancer Institute. He is ABIM board certified in Internal Medicine, Hematology and Medical Oncology.
David Apelian, MD, PhD, MBA Dr. Apelian's therapeutic area experience includes inflammatory bowel disease, hepatitis C and hepatitis B. Dr. Apelian came to GlobeImmune from Bristol-Myers Squibb where he served as a Clinical Director in the Infectious Diseases Group acting as medical lead for clinical development for the Baraclude (entecavir) NDA filing and approval in chronic hepatitis B. Prior to that, he served as Clinical Director in the Department of Hepatology / Gastroenterology at Schering Plough where he was medical lead on the pediatric sNDA for Rebetron for chronic HCV. Dr. Apelian received his M.D. from the University of Medicine and Dentistry of New Jersey, a Ph.D. in Biochemistry from Rutgers University, and an M.B.A. from Quinnipiac University. Dr. Apelian is board certified in Pediatrics.
Philippe Biship, MD Dr. Bishop is Vice President Clinical Development, Avastin at Genentech since December 2007 when he joined the company. Dr. Bishop’s responsibilities include overseeing the clinical programs for Avastin, the first FDA approved therapy designed to inhibit engiogenesis. Currently, the global development for Avastin includes more than 400 clinical trials in more than 20 different tumor types, including early-stage cancers. Previously Dr. Bishop held varying positions in industry and government. He was Senior Director in Oncology at Johnson & Johnson overseeing the global development of VELCADE and Doxil, Global Clinical Director/Distinguished Scientist at Sanofi-Aventis responsible for the clinical development of Genasense and alliance partnership with Genta, Inc., and also at the Food and Drug Administration. At the FDA, Dr. Bishop held the position of Acting Associate Director for Policy and Special Assistant to the Office Director in the Office of Therapeutics Research and Review in the Center for Biologics Evaluation and Research and was a Team Leader and Medical Officer in the Division of Clinical Trial Design and Analysis (oversight and/or contribution to approvals or ODAC presentations on Zevalin/Bexaar/Neulasta/Intron- A/Melacine). His contributions to policies on gene therapy and to the creation of the NIH Genetic Modification Clinical Research Information System (GeMCRIS®) earned him the US Department of Health and Human Services Secretary’s Award for Distinguished Service one of the highest honors presented by HHS Secretary Tommy G. Thompson. Dr. Bishop was an HHMI-NCI research scholar and earned his M.D. from the University of Nevada School of Medicine, completed training in internal medicine at University of Washington School of Medicine, and went on to a medical oncology fellowship at the National Cancer Institute (NCI).
Thomas J. Lynch, MD Dr. Lynch is Chief of Hematology and Oncology and Director of the Center for Thoracic Cancers at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Lynch served as a fellow in medical oncology at the Dana Farber Cancer Institute, joined the Kenneth B. Schwartz Center in 1996, and became Medical Director in 2000. In 2002, he assumed responsibility for the direction of the Oncology Service Line at Partners Healthcare. As director of the MGH Thoracic Oncology Center, Dr. Lynch has worked with advanced fellows in thoracic oncology, leading to important contributions in developmental therapeutics, molecular epidemiology, and clinical economics. He is the author of numerous publications and maintains a vigorous clinical practice.
Renato G. Martins, MD, MPH Dr. Martins, a native of Brazil, is medical director of thoracic and head and neck oncology at SCCA and an assistant professor of medicine at the University of Washington School of Medicine.
After completing medical school in Brazil, Dr. Martins came to the United States for further training. He did a fellowship in hematology/oncology at Massachusetts General Hospital and Harvard Medical School while also earning a master's degree in public health at Harvard in 1998.
Dr. Martins then returned to Brazil, where he was chief of medical oncology at the Brazilian National Cancer Institute in Rio de Janero until he accepted his present positions at SCCA and the University of Washington. He arrived in Seattle in February 2004.